YOUR SEARCH FOR Text 77 RESULTS
51 of Total
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance
… 2023 Financial Guidance and Updates on Key Clinical Programs February 7, 2023 at 7:00 AM … and provides a status update on the Company’s clinical development portfolio. "We are entering …
52 of Total
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advance
… disease. 13 About POD1UM The POD1UM (PD1 Clinical Program in Multiple Malignancies) clinical trial program for retifanlimab includes …
53 of Total
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalido
… about the study, please visit https://clinicaltrials.gov/study/NCT04680052 . About … research and development and the results of clinical trials possibly being unsuccessful or …
54 of Total
Portfolio: MPNs & GVHD, Hematology/Oncology, Dermatology & Inflammation and Autoimmunity
… Explore Our Science We have a breadth of clinical trial programs across Hematology, … (IAI). NAVIGATE TO PORTFOLIO DETAILS CLINICAL TRIALS Our Portfolio Molecular Targets …
55 of Total
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results | Incyte
… regulatory approvals and several important clinical milestones, allowing us to advance … of the year, we expect to have fourteen pivotal clinical trials underway. Incyte enters 2026 …
56 of Total
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatm
… the standard-of-care options available to clinicians and underscores our commitment to … patients in the placebo combination group. 1 Clinically meaningful improvement was also …
57 of Total
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates | Incyte
… the continued investment in mid- and late-stage clinical development programs and commercial … a manageable tolerability profile and clinical efficacy across multiple tumors, …
58 of Total
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance
… demonstrating a statistically significant and clinically meaningful improvement in … (JAK2V617Fi) Myelofibrosis: Phase 1 1 Clinical development of axatilimab in GVHD …
59 of Total
Innovating for Patients: A Day in the Life of Dija Atta | Incyte.com
… Incyte, and for Dija Atta, Senior Director of Clinical Operations, each day is driven by this … culture, Dija and her team seek to expedite clinical development and increase representation …
60 of Total
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Derm
… JAK1 selective inhibitor currently in Phase 3 clinical trials for HS, vitiligo and prurigo … the presentation of data from Incyte’s clinical development pipeline and the potential …